NCT04478279 2026-02-09A Phase 1-2 Study of ST101 in Patients With Advanced Solid TumorsSapience TherapeuticsPhase 1/2 Active not recruiting125 enrolled
NCT02974738 2025-07-10MK-6482-001Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 1 Active not recruiting120 enrolled
NCT04521686 2025-06-27Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsEli Lilly and CompanyPhase 1 Active not recruiting200 enrolled
NCT04913337 2024-10-02Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesNGM Biopharmaceuticals, IncPhase 1/2 Active not recruiting179 enrolled